PXD064007

PXD064007 is an original dataset announced via ProteomeXchange.

Title	Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer
Description	Background: Anaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited promising treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could be achieved by measurement of extracellular vesicle (EV)-associated cell-free RNA in liquid biopsy samples. Recent studies have discovered the potential of the receptor tyrosine kinase inhibitor vandetanib for ATC treatment in vitro and in vivo. Given the rarity of ATC patients receiving off-label vandetanib treatment, acquiring patient samples for clinical studies is a prolonged process, and pre-clinical investigations are needed to elucidate the effects of vandetanib on ATC cells. Objective: Here, we present an in vitro study addressing the holistic transcriptional and proteomic changes induced in the ATC cell line Cal62 by three doses of vandetanib and quantified by high-throughput methods. Methods: By comparing the transcriptional and proteomic data sets and applying dimensional reduction models such as sparse partial least-squares discriminant analysis, we refined a set of 21 biomarker candidates. Results: Out of these, we report a final signature of eight transcriptional biomarkers, validated in the cellular and cell-free RNA by RT-qPCR and verified for their biological significance and discriminatory power by pathway over-representation analysis and partial least-squares regression. This transcriptional biomarker signature can distinguish vandetanib treatment from the control in cell-free RNA isolated from Cal62 EVs and can be measured reliably, easily, and quickly using RT-qPCR. Conclusions: Our findings may serve as a basis for future clinical trials with liquid biopsy samples from ATC patients undergoing off-label vandetanib treatment.
HostingRepository	PRIDE
AnnounceDate	2025-09-09
AnnouncementXML	Submission_2025-09-09_07:11:23.641.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Christina Ludwig
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iodoacetamide derivatized residue
Instrument	Orbitrap Exploris 480

Revision	Datetime	Status	ChangeLog Entry
0	2025-05-16 02:35:16	ID requested
⏵ 1	2025-09-09 07:11:24	announced

Dataset with its publication pending

submitter keyword: Anaplastic thyroid cancer, vandetanib, Extracellular vesicles, dose-dependent transcriptomics and proteomics

Christina Ludwig
contact affiliation	Bavarian Center for Biomolecular Mass Spectrometry Technische Universität München Gregor-Mendel-Straße 4 85354 Freising GERMANY
contact email	tina.ludwig@tum.de
lab head
Christina Ludwig
contact affiliation	TU Munich
contact email	tina.ludwig@tum.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/09/PXD064007

PRIDE project URI

• PRIDE
  1. PXD064007
     1. Label: PRIDE project
     2. Name: Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer